Top news of the day from across the health care landscape.
A new clinical trial will test whether cannabidiol (CBD) products are safe to use as a treatment for Parkinson disease (PD)-related psychosis, MD Magazine reported. According to the article, a team of researchers will be conducting a phase 2 clinical trial testing the safety and efficacy of CBD to alleviate psychosis symptoms characterized by hallucinations and delusions. The trial, which represents the first ever large-scale trial testing CBD for PD, is expected to begin with a 6-week pilot to assess the safety, tolerability, and effectiveness of pharmaceutical-grade CBD in patients, the article reported.
Ancestry, a consumer genetics company, is releasing new genetic testing products that will give consumers health information based on DNA results, STAT reported. According to the article, AncestryHealth products will be ordered by a physician who works for PWN Health, a New York-based network of physicians, and will offer access to professional genetic counselors. AncestryHealth tests will be able to identify genes that increase the risk for hereditary breast and ovarian cancers, Lynch syndrome, cardiomyopathy, familial hypercholesterolemia, hereditary hemochromatosis, thrombophilia, sickle cell anemia, and cystic fibrosis, the article reported.
The CDC released a new guidance for clinicians whose patients have lung illnesses related to vaping, The Hill reported. According to the article, the official guidance recommended that clinicians maintain a high index of suspicion of influenza and other respiratory infections in all individuals with symptoms who also have a history of use of e-cigarette or vaping products, but also consider that any given individual may have a lung injury. The guidance also recommended follow up with patients within 1 or 2 weeks after being discharged from the hospital, the article reported.